Chongqing Qingyutang Pharmaceutical Co. Ltd.

Primary Study Objective: Using Leboresen tablets (5mg) manufactured by Qingyutang Pharmaceutical Co., Ltd. (a subsidiary of Fu'an Pharmaceutical Group) as the test formulation (T), and following relevant bioequivalence testing regulations, using Leboresen tablets (trade name: DAYVIGO®, 5mg) certified by Aezai Co., Ltd. as the reference formulation (R), a bioequivalence study was conducted. Secondary Study Objective: To observe the safety of the test and reference formulations of Leboresen tablets in healthy subjects.

Primary Study Objective: To conduct a bioequivalence study using oxazepam tablets (15mg) manufactured by Qingyutang Pharmaceutical Co., Ltd. (a subsidiary of Fu'an Pharmaceutical Group) as the test formulation (T), and oxazepam tablets (15mg, trade name: Sobril®) manufactured by Pfizer AS as the reference formulation (R), in accordance with relevant bioequivalence study regulations. Secondary Study Objective: To observe the safety of the test formulation oxazepam tablets and the reference formulation oxazepam tablets in healthy subjects.

Primary Study Objective: To assess the bioequivalence of a single oral dose of the test formulation (5 mg, manufactured by Qingyutang Pharmaceutical Co., Ltd., Fu'an Pharmaceutical Group) and the reference formulation (trade name: DAYVIGO®, 5 mg, licensed by Aezai Co., Ltd.) of Leborexen tablets in healthy subjects after a meal. Secondary Study Objective: To observe the safety of the test and reference formulations of Leborexen tablets in healthy subjects.